Annovis Bio Reports Positive Results from Final Phase of $1.9M NIH Funded Chronic Toxicology Study for its Lead Compound for ...
November 12 2020 - 6:45AM
Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug
platform company addressing Alzheimer’s disease (AD), Parkinson’s
disease (PD) and other neurodegenerative diseases, today announced
it successfully completed the dog cohort of a chronic toxicology
study of its lead therapeutic compound ANVS401 for the treatment of
AD and PD, reporting no negative side effects.
The nine-month dog study was part of a series of
animal toxicology studies, funded by a $1.9 million grant from the
National Institutes of Health that began in the fourth quarter of
2019. The strong safety data corroborates the positive results from
the Company’s prior one-month safety studies in mice, rats, dogs,
and humans and six-month study in rats.
Maria Maccecchini, Ph.D., CEO, commented, “The
strong safety profile observed in ANVS401 in our chronic tox study
in dogs is another important milestone for Annovis. Our chronic
toxicology studies, which are key to enabling us to conduct
long-term human studies, provide a solid foundation for ANVS401 as
we continue to recruit and treat patients for our two active Phase
2a clinical trials. We intend to report interim data on our Phase
2a clinical trials in the first quarter of 2021.”
About Annovis
Bio
Headquartered in Berwyn, Pennsylvania, Annovis
Bio, Inc. (Annovis) is a clinical-stage, drug platform company
addressing neurodegeneration, such as Alzheimer’s disease (AD),
Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS).
We believe that we are the only company developing a drug for AD,
PD and AD-DS that inhibits more than one neurotoxic protein and,
thereby, improves the information highway of the nerve cell, known
as axonal transport. When this information flow is impaired, the
nerve cell gets sick and dies. We expect our treatment to improve
memory loss and dementia associated with AD and AD-DS, as well as
body and brain function in PD. We have an ongoing Phase 2a study in
AD patients and have commenced a second Phase 2a study in AD and PD
patients. For more information on Annovis, please visit the
company’s website: www.annovisbio.com.
Forward-Looking Statements
Statements in this press release contain
“forward-looking statements” that are subject to substantial risks
and uncertainties. Forward-looking statements contained in this
press release may be identified by the use of words such as
“anticipate,” “expect,” “believe,” “will,” “may,” “should,”
“estimate,” “project,” “outlook,” “forecast” or other similar
words, and include, without limitation, statements regarding the
timing, effectiveness and anticipated results of ANVS401 clinical
trials. Forward-looking statements are based on Annovis Bio, Inc.’s
current expectations and are subject to inherent uncertainties,
risks and assumptions that are difficult to predict. Further,
certain forward-looking statements are based on assumptions as to
future events that may not prove to be accurate, including that
clinical trials may be delayed. These and other risks and
uncertainties are described more fully in the section titled “Risk
Factors” in the Annual Report on Form 10-K for the year ended
December 31, 2019 filed with the Securities and Exchange
Commission. Forward-looking statements contained in this
announcement are made as of this date, and Annovis Bio, Inc.
undertakes no duty to update such information except as required
under applicable law.
Investor Relations:
Dave Gentry, CEORedChip Companies
Inc.407-491-4498Dave@redchip.com
SOURCE: Annovis Bio, Inc.
Annovis Bio (NYSE:ANVS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Annovis Bio (NYSE:ANVS)
Historical Stock Chart
From Apr 2023 to Apr 2024